Innovative Nano-Biosensor Developed for Rapid Detection of Viruses
|
By LabMedica International staff writers Posted on 23 Mar 2016 |

Image: A novel nano-biosensor has been developed for lower-cost, rapid virus detection based on upconversion luminescence resonance energy transfer (LRET) technology and DNA oligo hybridization. Testing takes only 2–3 hours, about 10x faster traditional clinical methods (Photo courtesy of the Hong Kong Polytechnic University).
Scientists have invented a compact, easy-to-use biosensor for rapid, sensitive detection of flu and other viruses by utilizing the optical method of upconversion luminescence resonance energy transfer (LRET).
The new method, invented by researchers at the Hong Kong Polytechnic University (PolyU; Hong Kong), involves simple operational procedures that significantly reduce testing time from around 1–3 days to 2–3 hours, making it over 10 times quicker than traditional clinical methods. Furthermore, it is a low-cost test—about 80% lower than traditional tests, and the technology can be widely used to detect different types of viruses
RT-PCR is expensive and time-consuming while the sensitivity for ELISA is relatively low. Such limitations make these methods difficult for use in front-line and on-site virus detection. This challenge paved the way for the researchers to develop a new biosensor based on the luminescent technique.
The luminescent technique operates analogous to two matching pieces of magnet with attraction force. It involves the development of upconversion nanoparticles (UCNPs) conjugated with an oligo probe whose DNA base pairs are complementary with that of the gold nanoparticles (AuNPs) flu virus oligo. Given the complementarity, the two oligos undergo DNA-DNA hybridization. Upon being illuminated by a portable near-infrared laser pen, the UCNPs emit eye-visible green light while the AuNPs would absorb the green light. One can easily quantify the concentration of the targeted flu virus by measuring the decrease in green light intensity.
Initially, the researchers used upconversion LRET for ultrasensitive virus detection in liquid-phase system. The team then further improved the sensitivity by using a solid-phased nanoporous membrane system (NAAO). As NAAO membrane consists of many hollow channels, it allows more space for oligo hybridization to take place, increasing sensitivity by over 10 folds compared to the liquid-phase system, based on detection using inactivated virus samples.
The new biosensor does not require expensive instruments and sophisticated operational skills, and has sensitivity comparable to traditional clinical methods. In comparison to conventional downconversion luminescent technique, it causes low damage to genetic materials and does not induce background fluorescence. In addition, a complementary probe can be designed to target detection of any virus with known genetic sequence. In other words, the new method can be widely used for the detection of different types of viruses simply by modifying the UCNPs capture probe.
The team will continue to enhance the biosensor for virus detection, including increasing sensitivity and specificity, and developing a matrix for multiplex detection of multiple flu viruses on a single testing platform.
The related results have been recently published in the two nanomaterial research journals ACS Nano and Small.
Related Links:
The Hong Kong Polytechnic University
The new method, invented by researchers at the Hong Kong Polytechnic University (PolyU; Hong Kong), involves simple operational procedures that significantly reduce testing time from around 1–3 days to 2–3 hours, making it over 10 times quicker than traditional clinical methods. Furthermore, it is a low-cost test—about 80% lower than traditional tests, and the technology can be widely used to detect different types of viruses
RT-PCR is expensive and time-consuming while the sensitivity for ELISA is relatively low. Such limitations make these methods difficult for use in front-line and on-site virus detection. This challenge paved the way for the researchers to develop a new biosensor based on the luminescent technique.
The luminescent technique operates analogous to two matching pieces of magnet with attraction force. It involves the development of upconversion nanoparticles (UCNPs) conjugated with an oligo probe whose DNA base pairs are complementary with that of the gold nanoparticles (AuNPs) flu virus oligo. Given the complementarity, the two oligos undergo DNA-DNA hybridization. Upon being illuminated by a portable near-infrared laser pen, the UCNPs emit eye-visible green light while the AuNPs would absorb the green light. One can easily quantify the concentration of the targeted flu virus by measuring the decrease in green light intensity.
Initially, the researchers used upconversion LRET for ultrasensitive virus detection in liquid-phase system. The team then further improved the sensitivity by using a solid-phased nanoporous membrane system (NAAO). As NAAO membrane consists of many hollow channels, it allows more space for oligo hybridization to take place, increasing sensitivity by over 10 folds compared to the liquid-phase system, based on detection using inactivated virus samples.
The new biosensor does not require expensive instruments and sophisticated operational skills, and has sensitivity comparable to traditional clinical methods. In comparison to conventional downconversion luminescent technique, it causes low damage to genetic materials and does not induce background fluorescence. In addition, a complementary probe can be designed to target detection of any virus with known genetic sequence. In other words, the new method can be widely used for the detection of different types of viruses simply by modifying the UCNPs capture probe.
The team will continue to enhance the biosensor for virus detection, including increasing sensitivity and specificity, and developing a matrix for multiplex detection of multiple flu viruses on a single testing platform.
The related results have been recently published in the two nanomaterial research journals ACS Nano and Small.
Related Links:
The Hong Kong Polytechnic University
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read more
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








